Pomalidomide with brand name Imnovid, is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013, by the US Food and Drug Administration as a treatment for relapsed and refractory multiple myeloma.
